Imipenem/Cilastatin Actavis

Imipenem, the active ingredient in Imipenem/Cilastatin Actavis, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous or inhalation use. It treats severe bacterial infections in hospitalized patients, including intra‑abdominal, urinary tract, and respiratory infections. GNH USA supplies Imipenem/Cilastatin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used to treat serious bacterial infections in the hospital setting. - Complicated intra‑abdominal infections: provides effective bacterial eradication in severe abdominal sepsis. - Complicated urinary tract infections: clears resistant uropathogens causing pyelonephritis and cystitis. - Hospital‑acquired and ventilator‑associated pneumonia: combats multidrug‑resistant organisms in lower respiratory infections. - Skin and soft‑tissue infections: treats deep or necrotizing infections caused by Gram‑negative and Gram‑positive bacteria. - Febrile neutropenia: offers rapid coverage against potential bloodstream pathogens in immunocompromised patients.

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis following infusion. - Diarrhea: may range from loose stools to mild colitis. - Headache: transient cranial discomfort. - Rash: skin erythema or pruritus. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: risk increases with high doses or renal impairment. - Anaphylaxis: severe hypersensitivity reaction requiring immediate medical attention. - Clostridioides difficile‑associated diarrhea: possible severe colitis. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare but life‑threatening skin reactions. - Severe neutropenia or thrombocytopenia: marked reduction in blood cell counts. - Acute renal failure: abrupt loss of kidney function, especially in predisposed patients.

Use imipenem/cilastatin with careful clinical monitoring. - Renal impairment: adjust dose based on creatinine clearance to avoid accumulation. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Seizure risk: avoid in patients with a history of epilepsy or CNS disorders unless benefits outweigh risks. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk to fetus or infant. - Concomitant valproic acid: monitor for reduced valproate levels and possible seizure breakthrough. - Store at ambient temperature: keep in original container, protect from moisture and light.

Imipenem/cilastatin may interact with several medications.

Major Interactions (Avoid): - Valproic acid: reduces serum valproate concentrations, increasing seizure risk. - Other carbapenems: concurrent use may lead to additive toxicity without added benefit. - Nephrotoxic agents (e.g., aminoglycosides): heightened risk of renal injury.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance, requiring dose adjustment. - Anticoagulants (warfarin): monitor INR for potential alteration. - Oral contraceptives: possible reduction in efficacy, advise alternative contraception. - NSAIDs: increased risk of renal dysfunction, especially in dehydrated patients. - Phenytoin: may lower phenytoin levels, necessitate therapeutic drug monitoring.